BridgeBio Oncology initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of BridgeBio Oncology (BBOT) with an Overweight rating and $20 price target The clinical-stage company is focused on developing therapies for cancers driven by RAS pathway mutations, notes the analyst, who adds that its pipeline addresses significant unmet needs in oncology by targeting high-prevalence tumor types. The firm sees an opportunity for “meaningful value inflection ahead” in “a catalyst-rich 2026” with clinical data expected across its three programs, the analyst tells investors.